Company news
Genelux Corporation (NASDAQ:GNLX) news
Genelux Corporation news releases on 6ix. Latest, Sep 9, 2026: Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell…
Press releases & updates
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
September 9, 2026
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
August 13, 2026
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
June 30, 2026
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
May 7, 2026
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 19, 2026
Genelux Corporation to Participate in Upcoming Conferences
February 18, 2026
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
January 12, 2026
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
January 8, 2026
Genelux Corporation Announces Proposed Public Offering of Common Stock
January 7, 2026
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
January 5, 2026
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
January 2, 2026
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
November 5, 2025
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
September 2, 2025
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
August 7, 2025
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
July 7, 2025
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
May 6, 2025
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
May 1, 2025
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 28, 2025
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
March 25, 2025
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
March 25, 2025
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
March 25, 2025
Genelux Corporation Announces New Chief Financial Officer
February 2, 2025
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
November 13, 2024
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
October 21, 2024
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
August 13, 2024
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
May 23, 2024
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 22, 2024
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 8, 2024
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 31, 2024
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 26, 2023
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
November 13, 2023
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2023
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
August 13, 2023
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
July 19, 2023
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
July 9, 2023
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
June 21, 2023
Genelux Corporation Announces $18 Million Private Placement
June 11, 2023
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA...
May 24, 2023
Genelux Corporation Announces $33 Million Private Placement
May 14, 2023
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
March 22, 2023